CVS Health Files 8-K Report

TL;DR

CVS filed a standard 8-K, no major news.

AI Summary

On March 5, 2024, CVS Health Corporation filed an 8-K report. The filing primarily serves as a notification of events and does not disclose specific new financial figures or material business changes. It confirms the company's ongoing reporting status and standard corporate information.

Why It Matters

This filing indicates routine corporate reporting by CVS Health, confirming its compliance with SEC regulations without revealing new material information.

Risk Assessment

Risk Level: low — The filing is a routine 8-K report and does not contain any new material information that would impact risk.

Key Players & Entities

• CVS HEALTH Corp (company) — Registrant
• 0000064803 (company) — Central Index Key
• 001-01011 (company) — SEC File Number
• 05-0494040 (company) — IRS Employer Identification No.
• March 5, 2024 (date) — Date of Report

FAQ

Key Financial Figures

• $0.01 — ich registered Common Stock, par value $0.01 per share CVS New York Stock Exchange
• $7 — per share ("EPS") guidance of at least $7.06, its full-year 2024 Adjusted EPS gui
• $8 — 2024 Adjusted EPS guidance of at least $8.30, and its full-year 2024 cash flow fr
• $12.0 billion — ow from operations guidance of at least $12.0 billion. In addition, during the webcast Mr. Co

Filing Documents

• cvs-20240305.htm (8-K) — 40KB
• cvs-20240305_g1.jpg (GRAPHIC) — 4KB
• 0000064803-24-000009.txt ( ) — 175KB
• cvs-20240305.xsd (EX-101.SCH) — 2KB
• cvs-20240305_lab.xml (EX-101.LAB) — 24KB
• cvs-20240305_pre.xml (EX-101.PRE) — 12KB
• cvs-20240305_htm.xml (XML) — 3KB

01 Regulation FD Disclosure

Item 7.01 Regulation FD Disclosure. On March 5, 2024, members of CVS Health Corporation's ("CVS Health," the "Company," "we" or "our") senior management team will meet with investors and Executive Vice President and Chief Financial Officer Tom Cowhey will participate in a webcast at 9:50 a.m. (Eastern Time). During the meetings and webcast, the senior management team will reaffirm the Company's previously announced full-year 2024 GAAP diluted earnings per share ("EPS") guidance of at least $7.06, its full-year 2024 Adjusted EPS guidance of at least $8.30, and its full-year 2024 cash flow from operations guidance of at least $12.0 billion. In addition, during the webcast Mr. Cowhey will provide updates on recent business trends and initiatives. An audio webcast of the presentation will be broadcast simultaneously for all interested parties through the Investor Relations portion of the CVS Health website at http://investors.cvshealth.com, and a replay of the webcast will be archived for one year. Non-GAAP Financial Measures This Current Report on Form 8-K includes projected Adjusted EPS, which represents a non-GAAP financial measure. The Company uses non-GAAP financial measures to analyze underlying business performance and trends. The Company believes that providing non-GAAP financial measures enhances the Company's and investors' ability to compare the Company's past financial performance with its current performance. Non-GAAP financial measures should not be considered a substitute for, or superior to, financial measures determined or calculated in accordance with GAAP. The Company's definitions of its non-GAAP financial measures may not be comparable to similarly titled measures reported by other companies. The most directly comparable GAAP measure is projected GAAP diluted EPS. Projected GAAP diluted EPS and projected Adjusted EPS, respectively, are calculated by dividing projected net income attributable to CVS Health and projected adjusted income attri

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. CVS HEALTH CORPORATION Date: March 5, 2024 By: /s/ Thomas F. Cowhey Thomas F. Cowhey Executive Vice President and Chief Financial Officer

View Full Filing

View this 8-K filing on SEC EDGAR